Payment overview · 2025
General Payments
$2,239.56
142 reported records · 16 companies
Healthcare provider profile · identity verified
Shane E Kelley, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · KNOXVILLE, TN · NPI 1891007605
Verified facts
What the public records show
CMS Open Payments records show Shane E Kelley, M.D. received $2,239.56 in general payments during 2025 across 142 reported records.
PFIZER INC. accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $316.46 | 14.1% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $313.49 | 14.0% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $307.94 | 13.8% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $243.56 | 10.9% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $215.73 | 9.6% | 17 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $204.61 | 9.1% | 27 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $175.81 | 7.8% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $121.33 | 5.4% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $85.93 | 3.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $82.92 | 3.7% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $36.55 | 1.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.32 | 1.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.70 | 1.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $30.68 | 1.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.36 | 0.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.17 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,239.56 | 142 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $229.99 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $212.55 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $208.31 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $204.61 | 27 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $204.61 | 27 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $175.81 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $161.29 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $140.41 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $139.85 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $139.58 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $136.81 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $125.08 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $125.08 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $124.38 | 10 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $121.33 | 6 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $120.32 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $108.84 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $85.93 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $82.92 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $66.32 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63.95 | 7 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $43.08 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $40.54 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.70 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $30.68 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $12.60 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $12.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 128 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 71 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 61 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
105 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
61 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 776 | 186 |
| Atorvastatin Calcium | Atorvastatin Calcium | 615 | 177 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 560 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 521 | 128 |
| Omeprazole | Omeprazole | 456 | 121 |
| Lisinopril | Lisinopril | 433 | 120 |
| Pantoprazole Sodium | Pantoprazole Sodium | 296 | 84 |
| Losartan Potassium | Losartan Potassium | 258 | 64 |
| Metformin Hcl Er | Metformin Hcl | 225 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 63 |
| Famotidine | Famotidine | 219 | 71 |
| Potassium Chloride | Potassium Chloride | 208 | 61 |
| Simvastatin | Simvastatin | 205 | 54 |
| Trazodone Hcl | Trazodone Hcl | 202 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 200 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 198 | 55 |
| Furosemide | Furosemide | 196 | 61 |
| Glipizide Er | Glipizide | 196 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 192 | 57 |
| Montelukast Sodium | Montelukast Sodium | 172 | 51 |
| Meloxicam | Meloxicam | 162 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 162 | 48 |
| Allopurinol | Allopurinol | 154 | 45 |
| Gabapentin | Gabapentin | 150 | 38 |
| Sertraline Hcl | Sertraline Hcl | 147 | 38 |
| Benazepril Hcl | Benazepril Hcl | 142 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 36 |
| Metformin Hcl | Metformin Hcl | 134 | 39 |
| Alendronate Sodium | Alendronate Sodium | 130 | 36 |
| Eliquis | Apixaban | 128 | 31 |
| Alprazolam | Alprazolam | 123 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 32 |
| Synthroid | Levothyroxine Sodium | 105 | 22 |
| Buspirone Hcl | Buspirone Hcl | 104 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 102 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 21 |
| Warfarin Sodium | Warfarin Sodium | 91 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 88 | 28 |
| Lovastatin | Lovastatin | 88 | 25 |
| Carvedilol | Carvedilol | 87 | 23 |
| Fenofibrate | Fenofibrate | 86 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 83 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 30 |
| Glipizide | Glipizide | 75 | 18 |
| Tramadol Hcl | Tramadol Hcl | 75 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 35 |
| Methylprednisolone | Methylprednisolone | 72 | 62 |
| Jardiance | Empagliflozin | 71 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 67 | 18 |
| Ozempic | Semaglutide | 66 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 18 |
| Bupropion Xl | Bupropion Hcl | 62 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 61 | 51 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 13 |
| Lorazepam | Lorazepam | 55 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 53 | 14 |
| Celecoxib | Celecoxib | 52 | 19 |
| Mounjaro | Tirzepatide | 51 | 12 |
| Spironolactone | Spironolactone | 51 | 16 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 49 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 12 |
| Diazepam | Diazepam | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 46 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 45 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 28 |
| Valsartan | Valsartan | 43 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 40 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Topiramate | Topiramate | 42 | 11 |
| Finasteride | Finasteride | 40 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 14 |
| Atenolol | Atenolol | 39 | 12 |
| Bumetanide | Bumetanide | 39 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 11 |
| Nabumetone | Nabumetone | 34 | 15 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Methocarbamol | Methocarbamol | 31 | 11 |
| Donepezil Hcl | Donepezil Hcl | 30 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | 11 |
| Irbesartan | Irbesartan | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | 12 |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Cefdinir | Cefdinir | 23 | 21 |
| Mupirocin | Mupirocin | 23 | 20 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Prednisone | Prednisone | 22 | 15 |
| Rybelsus | Semaglutide | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 18 |
| Testosterone | Testosterone | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 12 |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Gemtesa | Vibegron | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Naproxen | Naproxen | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,239.56 · 142 records | PFIZER INC. | AIRSUPRA, AREXVY, BEXSERO, BREZTRI, CAMZYOS, ELIQUIS, ENHERTU, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PEDIARIX, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error